福安药业：公司产品被纳入新版国家医保药品目录

Core Viewpoint - Fu'an Pharmaceutical (300194) announced on December 8 that its subsidiary's product, Peramivir Injection, has been newly included in the National Medical Insurance Drug List for 2025, which is used for the treatment of influenza A or B [1] Company Summary - Fu'an Pharmaceutical's subsidiary has successfully added Peramivir Injection to the National Medical Insurance Drug List for 2025 [1] - The inclusion of this product is significant as it expands the treatment options available for influenza A and B [1] Industry Summary - The addition of Peramivir Injection to the National Medical Insurance Drug List indicates a positive trend in the pharmaceutical industry regarding the accessibility of antiviral treatments [1] - This move may enhance the competitive landscape for companies involved in the production of antiviral medications [1]